🇺🇸 Clarithromycin 250 MG in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Chronic Obstructive Pulmonary Disease — 1 report (10%)
  2. Dyspnoea — 1 report (10%)
  3. Electrocardiogram Qt Prolonged — 1 report (10%)
  4. Erythema — 1 report (10%)
  5. Lower Respiratory Tract Infection — 1 report (10%)
  6. Pharyngeal Swelling — 1 report (10%)
  7. Pneumonia — 1 report (10%)
  8. Stevens-Johnson Syndrome — 1 report (10%)
  9. Swelling Face — 1 report (10%)
  10. Swollen Tongue — 1 report (10%)

Source database →

Clarithromycin 250 MG in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Clarithromycin 250 MG approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Clarithromycin 250 MG in United States?

The University of Hong Kong is the originator. The local marketing authorisation holder may differ — check the official source linked above.